Delgocitinib for Hair Loss

This trial tests a cream called delgocitinib to determine its safety and effectiveness in treating hair loss caused by two specific conditions: lichen planopilaris (a type of scarring hair loss) and central centrifugal cicatricial alopecia (a condition leading to hair loss on the scalp). Participants will apply the cream twice daily for 48 weeks. Researchers aim to understand how the cream affects these conditions and monitor any side effects. The study seeks individuals who have experienced hair loss from either condition for at least six months and can commit to regular study visits. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Yes, you may need to stop certain medications before joining the trial. Specifically, you must not use systemic immunosuppressive medications, certain non-biologic systemic agents, intralesional corticosteroids, oral JAK inhibitors, or specific topical treatments within a specified period before the baseline visit.

Research has shown that delgocitinib cream is generally safe and well-tolerated by patients. Various studies have consistently confirmed its safety. Side effects, or unintended reactions, were similar to those from using a cream with no active ingredients. For instance, one study found that 13.3% of patients reported mild side effects, which were manageable and not serious.

Other studies have found that the cream does not significantly enter the bloodstream, reducing the risk of widespread side effects and making it safer for long-term use. Additionally, delgocitinib has been tested for other skin conditions like atopic dermatitis (a type of skin inflammation) and has proven safe for extended use.

Researchers are excited about Delgocitinib for treating hair loss conditions like Centrifugal Cicatricial Alopecia (CCCA) and Lichen Planopilaris (LPP) because it offers a novel approach. Unlike current treatments such as corticosteroids and immunosuppressants, which mainly focus on reducing inflammation, Delgocitinib is a Janus kinase (JAK) inhibitor. This means it directly targets and interferes with the pathways responsible for the inflammatory response, potentially offering more precise and effective relief. Additionally, by targeting these pathways, Delgocitinib might reduce side effects commonly associated with broader immunosuppressive therapies.

Research has shown that delgocitinib cream can improve skin conditions and might help with hair loss issues like CCCA and LPP. In this trial, participants with CCCA or LPP will receive delgocitinib as part of their treatment. Patients using delgocitinib experienced better hair density and fewer symptoms. In some cases, they grew about seven more hairs per square centimeter after treatment. The cream also improved key indicators of these conditions, suggesting it addresses the root problems. Additionally, delgocitinib has proven safe and effective over long periods, making it a promising option for hair loss related to these conditions.¹³⁴⁶⁷